e-learning
resources
European Respiratory Review
2008
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of chemokines and cytokines in lung fibrosis
Keane M. P.
Source:
Eur Respir Rev 2008; 17: 151-156
Journal Issue:
December 2008 - 17 (109)
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Keane M. P.. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev 2008; 17: 151-156
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
M2 polarized alveolar macrophages in pulmonary fibrosis
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases
Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Year: 2005
FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis
Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation
Year: 2018
Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 102s
Year: 2006
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Role of IL-11 in vascular function of pulmonary fibrosis patients
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 719s
Year: 2004
Role of IL23 in the development of fibrotic interstitial lung disease
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019
The RANKL-OPG balance in pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Role of Wnt-1, Wnt-3 and MMP-7 in fibrotic response in extrinsic allergic alveolitis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Interleukin-17 (IL-17) contributes to silica-induced alveolitis but is not essential in fibrosis development
Source: Eur Respir J 2006; 28: Suppl. 50, 675s
Year: 2006
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Disturbance of pro-inflammatory cytokine production in patients with cystic fibrosis lung disease
Source: Eur Respir J 2005; 26: Suppl. 49, 404s
Year: 2005
The pathogenesis of pulmonary fibrosis: a moving target
Source: Eur Respir J 2013; 41: 1207-1218
Year: 2013
Increased CCL18 production in interstitial lung diseases is associated with fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 38s
Year: 2004
High mobility group box protein 1 (HMGB1) production in highly vascularized alveolar lesions causes acute exacerbation in idiopathic pulmonary fibrosis
Source: Annual Congress 2005 - Progresses in lung fibrosis
Year: 2005
Apoptosis in lung injury and fibrosis
Source: Eur Respir J 2008; 32: 1631-1638
Year: 2008
Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases
Source: Eur Respir J 2008; 32: 1068-1081
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept